Based on the successful demonstration of the potential targeted-PDT of PSMA-YI-1 NPs in bladder cancer cells, the additional loading of chemo-drugs into the PSMA nanocarriers may result in better anticancer efficacy with lower dose administration for future chemotherapeutic strategies. Here, FOLH1 is linked to urinary bladder carcinoma.